Literature DB >> 33829368

Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management.

Amedeo Lonardo1, Juan Pablo Arab2,3, Marco Arrese2,3.   

Abstract

Precision medicine defines the attempt to identify the most effective approaches for specific subsets of patients based on their genetic background, clinical features, and environmental factors. Nonalcoholic fatty liver disease (NAFLD) encompasses the alcohol-like spectrum of liver disorders (steatosis, steatohepatitis with/without fibrosis, and cirrhosis and hepatocellular carcinoma) in the nonalcoholic patient. Recently, disease renaming to MAFLD [metabolic (dysfunction)-associated fatty liver disease] and positive criteria for diagnosis have been proposed. This review article is specifically devoted to envisaging some clues that may be useful to implementing a precision medicine-oriented approach in research and clinical practice. To this end, we focus on how sex and reproductive status, genetics, intestinal microbiota diversity, endocrine and metabolic status, as well as physical activity may interact in determining NAFLD/MAFLD heterogeneity. All these factors should be considered in the individual patient with the aim of implementing an individualized therapeutic plan. The impact of considering NAFLD heterogeneity on the development of targeted therapies for NAFLD subgroups is also extensively discussed.

Entities:  

Keywords:  Cirrhosis; Fibrosis; Metabolic syndrome; NAFLD; NASH; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Steatosis

Year:  2021        PMID: 33829368     DOI: 10.1007/s12325-021-01690-1

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  145 in total

1.  P4 medicine: how systems medicine will transform the healthcare sector and society.

Authors:  Mauricio Flores; Gustavo Glusman; Kristin Brogaard; Nathan D Price; Leroy Hood
Journal:  Per Med       Date:  2013       Impact factor: 2.512

Review 2.  Predictive, personalized, preventive, participatory (P4) cancer medicine.

Authors:  Leroy Hood; Stephen H Friend
Journal:  Nat Rev Clin Oncol       Date:  2011-03       Impact factor: 66.675

Review 3.  Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.

Authors:  Zobair Younossi; Frank Tacke; Marco Arrese; Barjesh Chander Sharma; Ibrahim Mostafa; Elisabetta Bugianesi; Vincent Wai-Sun Wong; Yusuf Yilmaz; Jacob George; Jiangao Fan; Miriam B Vos
Journal:  Hepatology       Date:  2019-06       Impact factor: 17.425

Review 4.  Nonalcoholic steatohepatitis in precision medicine: Unraveling the factors that contribute to individual variability.

Authors:  John D Clarke; Nathan J Cherrington
Journal:  Pharmacol Ther       Date:  2015-03-21       Impact factor: 12.310

Review 5.  Nonalcoholic Fatty Liver Disease 2020: The State of the Disease.

Authors:  Thomas G Cotter; Mary Rinella
Journal:  Gastroenterology       Date:  2020-02-13       Impact factor: 22.682

Review 6.  Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

Authors:  Zobair M Younossi; Aaron B Koenig; Dinan Abdelatif; Yousef Fazel; Linda Henry; Mark Wymer
Journal:  Hepatology       Date:  2016-02-22       Impact factor: 17.425

Review 7.  Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis.

Authors:  Björn Carlsson; Daniel Lindén; Gabriella Brolén; Mathias Liljeblad; Mikael Bjursell; Stefano Romeo; Rohit Loomba
Journal:  Aliment Pharmacol Ther       Date:  2020-05-07       Impact factor: 8.171

Review 8.  Enabling Precision Cardiology Through Multiscale Biology and Systems Medicine.

Authors:  Kipp W Johnson; Khader Shameer; Benjamin S Glicksberg; Ben Readhead; Partho P Sengupta; Johan L M Björkegren; Jason C Kovacic; Joel T Dudley
Journal:  JACC Basic Transl Sci       Date:  2017-06-26

Review 9.  Precision medicine in the era of artificial intelligence: implications in chronic disease management.

Authors:  Murugan Subramanian; Anne Wojtusciszyn; Lucie Favre; Sabri Boughorbel; Jingxuan Shan; Khaled B Letaief; Nelly Pitteloud; Lotfi Chouchane
Journal:  J Transl Med       Date:  2020-12-09       Impact factor: 5.531

View more
  9 in total

Review 1.  Histological assessment based on liver biopsy: the value and challenges in NASH drug development.

Authors:  Xiao-Fei Tong; Qian-Yi Wang; Xin-Yan Zhao; Ya-Meng Sun; Xiao-Ning Wu; Li-Ling Yang; Zheng-Zhao Lu; Xiao-Juan Ou; Ji-Dong Jia; Hong You
Journal:  Acta Pharmacol Sin       Date:  2022-02-14       Impact factor: 7.169

2.  Insight Into the Adolescent Patient Experience With Nonalcoholic Fatty Liver Disease.

Authors:  Sanita L Ley; Katherine M Kidwell; Tori R Van Dyk; Sarah Orkin; Cathleen Odar Stough; Taylor Howarth; Amy R Goetz; Stavra A Xanthakos; Kristin Bramlage; Marialena Mouzaki; Ana Catalina Arce-Clachar; Meg H Zeller
Journal:  J Pediatr Gastroenterol Nutr       Date:  2022-04-20       Impact factor: 3.288

Review 3.  Is there a role of lipid-lowering therapies in the management of fatty liver disease?

Authors:  Ismini Tzanaki; Aris P Agouridis; Michael S Kostapanos
Journal:  World J Hepatol       Date:  2022-01-27

4.  Metabolic-Associated Fatty Liver Disease Is Highly Prevalent in the Postacute COVID Syndrome.

Authors:  Jovana Milic; Sara Barbieri; Licia Gozzi; Alberto Brigo; Bianca Beghé; Alessia Verduri; Erica Bacca; Vittorio Iadisernia; Gianluca Cuomo; Giovanni Dolci; Dina Yaacoub; Emanuele Aprile; Michela Belli; Maria Venuta; Marianna Meschiari; Giada Sebastiani; Enrico Clini; Cristina Mussini; Amedeo Lonardo; Giovanni Guaraldi; Paolo Raggi
Journal:  Open Forum Infect Dis       Date:  2022-01-10       Impact factor: 3.835

5.  Adiposity, metabolomic biomarkers, and risk of nonalcoholic fatty liver disease: a case-cohort study.

Authors:  Yuanjie Pang; Christiana Kartsonaki; Jun Lv; Iona Y Millwood; Zammy Fairhurst-Hunter; Iain Turnbull; Fiona Bragg; Michael R Hill; Canqing Yu; Yu Guo; Yiping Chen; Ling Yang; Robert Clarke; Robin G Walters; Ming Wu; Junshi Chen; Liming Li; Zhengming Chen; Michael V Holmes
Journal:  Am J Clin Nutr       Date:  2022-03-04       Impact factor: 8.472

Review 6.  Nonalcoholic Fatty Liver Disease and Endocrine Axes-A Scoping Review.

Authors:  Madalena Von-Hafe; Marta Borges-Canha; Catarina Vale; Ana Rita Leite; João Sérgio Neves; Davide Carvalho; Adelino Leite-Moreira
Journal:  Metabolites       Date:  2022-03-29

7.  Effect of cofactors on NAFLD/NASH and MAFLD. A paradigm illustrating the pathomechanics of organ dysfunction.

Authors:  Amedeo Lonardo; Ashwani K Singal; Natalia Osna; Kusum K Kharbanda
Journal:  Metab Target Organ Damage       Date:  2022-08-22

8.  Clinical practice gaps and challenges in non-alcoholic steatohepatitis care: An international physician needs assessment.

Authors:  Patrice Lazure; Jeremy W Tomlinson; Kris V Kowdley; Paolo Magni; Raul D Santos; Ginny Jacobs; Suzanne Murray
Journal:  Liver Int       Date:  2022-06-09       Impact factor: 8.754

Review 9.  Cell Models and Omics Techniques for the Study of Nonalcoholic Fatty Liver Disease: Focusing on Stem Cell-Derived Cell Models.

Authors:  María Pelechá; Estela Villanueva-Bádenas; Enrique Timor-López; María Teresa Donato; Laia Tolosa
Journal:  Antioxidants (Basel)       Date:  2021-12-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.